Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.32 |
| ▸ | RAB9A | P51151 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | ACACB | O00763 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | TXN | P10599 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.30 |
| ▸ | MELK | Q14680 | 1/20 | 0.30 |
| ▸ | ABL1 | P00519 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2825212 | 0.90 | HPGD (0.34) | HPGDRAB9AMEN1KMT2AL3MBTL1 | |
| SCHEMBL2820533 | 0.90 | L3MBTL1 (0.34) | HPGDRAB9AMEN1KMT2AL3MBTL1 | |
| SCHEMBL2819903 | 0.86 | USP2 (0.36) | HPGDRAB9AMEN1KMT2AACACB | |
| SCHEMBL2823237 | 0.84 | KDR (0.31) | RAB9AMEN1KMT2AL3MBTL1KDM4E | |
| SCHEMBL2822064 | 0.84 | PTGS2 (0.36) | PTGS2RAB9AMEN1KMT2AKDM4E | |
| SCHEMBL2819564 | 0.81 | PTGS2 (0.37) | PTGS2HPGDACACBSMN1; SMN2LMNA | |
| SCHEMBL2818881 | 0.76 | KDM4E (0.33) | HPGDRAB9AMEN1KMT2AL3MBTL1 | |
| SCHEMBL2819937 | 0.76 | USP2 (0.38) | RAB9AMEN1KMT2AL3MBTL1KDM4E | |
| SCHEMBL2822997 | 0.76 | L3MBTL1 (0.33) | RAB9AMEN1KMT2AL3MBTL1NPC1 | |
| SCHEMBL2824191 | 0.73 | MAPT (0.36) | HPGDRAB9AMEN1KMT2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1386914-B1 | HALOGENATED QUINOLINE DERIVATIVES AND ECTOPARASITE CONTROLLERS | MEIJI SEIKA KAISHA (JP) | 2010-10-27 | — | — | EP | disclosed |
| US-7022855-B2 | Halogen-substituted quinoline derivatives and ectoparasite control agent | MEIJI SEIKA KAISHA, LTD. (JP) | 2006-04-04 | — | — | US | disclosed |
| EP-1559321-A1 | MIXED COMPOSITIONS FOR CONTROLLING PARASITIC INSECTS | MEIJI SEIKA KAISHA LTD. (JP) | 2005-08-03 | — | — | EP | disclosed |
| US-20040087618-A1 | Halogen-substituted quinoline derivatives and ectoparasite control agent | MEIJI SEIKA KAISHA, LTD. (JP) | 2004-05-06 | — | — | US | disclosed |
| US-20040077602-A1 | Mixture composition for controlling ectoparasites | MEIJI SEIKA KAISHA, LTD. (JP) | 2004-04-22 | — | — | US | disclosed |
| EP-1386914-A1 | HALOGENATED QUINOLINE DERIVATIVES AND ECTOPARASITE CONTROLLERS | MEIJI SEIKA KAISHA LTD. (JP) | 2004-02-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040087618-A1 | Halogen-substituted quinoline derivatives and ectoparasite control agent | ATL3, RABL3, RAB5C | PTGS2 4672/4885HPGD 4517/4885RAB9A 179/4885 |
| US-20040077602-A1 | Mixture composition for controlling ectoparasites | SF3A3, PEX3, HCN3 | PTGS2 4763/4885HPGD 4828/4885RAB9A 569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.